

Supplementary Table 1. Key patient characteristics by 1L therapy in mPAC

Characteristic	Overall (N = 9439)	1L FOLFIRINOX ^a (n = 2277)	1L Gem-Nab (n = 2605)
Age at diagnosis (y), mean (SD)	69.2 (9.8)	64.8 (8.9)	70.4 (9.1)
Sex, n (%)			
Male	4981 (52.8)	1287 (56.5)	1394 (53.5)
Female	4455 (47.2)	990 (43.5)	1211 (46.5)
Race and ethnicity, n (%)			
Non-Hispanic White	4784 (50.7)	1149 (50.5)	1275 (48.9)
Non-Hispanic Black	768 (8.1)	180 (7.9)	211 (8.1)
Asian	144 (1.5)	41 (1.8)	30 (1.2)
Hispanic and Latino	561 (5.9)	159 (7.0)	152 (5.8)
Others	433 (4.6)	86 (3.8)	150 (5.8)
Insurance coverage, n (%) ^b			
Commercial health plan	6874 (72.8)	1693 (74.4)	1981 (76.0)
Medicare	3537 (37.5)	651 (28.6)	1043 (40.0)
Medicaid	569 (6.0)	130 (5.7)	177 (6.8)
Self-pay	371 (3.9)	115 (5.1)	77 (3.0)
Practice setting, n (%)			
Community	6665 (70.6)	624 (27.4)	574 (22.0)
Academic	2774 (29.4)	1653 (72.6)	2031 (78.0)
ECOG PS, n (%)			
0/1	4779 (50.6)	1800 (79.1)	1877 (72.1)
2/3/4	1006 (10.7)	180 (7.9)	454 (17.4)
De novo metastatic disease, n (%)	5991 (63.5)	1887 (82.9)	1586 (60.9)
Liver metastasis, n (%)	1628 (17.2)	475 (20.9)	434 (16.7)
Germline BRCA 1 mutation status, n (%)			
Wild type	1280 (13.6)	194 (8.5)	399 (15.3)
Mutated	26 (0.3)	11 (0.5)	2 (0.1)
Unreported	8133 (86.2)	2072 (91)	2204 (84.6)
Germline BRCA 2 mutation status, n (%)			
Wild type	1264 (13.4)	198 (8.7)	394 (15.1)
Mutated	42 (0.4)	7 (0.3)	7 (0.3)
Unreported	8133 (86.2)	2072 (91)	2204 (84.6)
Somatic BRCA 1 mutation status, n (%)			
Wild type	717 (7.6)	79 (3.5)	219 (8.4)
Mutated	13 (0.1)	4 (0.2)	1 (<0.1)
Unreported	8709 (92.3)	2194 (96.4)	2385 (91.6)
Somatic BRCA 2 mutation status, n (%)			
Wild type	707 (7.5)	78 (3.4)	215 (8.3)
Mutated	23 (0.2)	5 (0.2)	5 (0.2)
Unreported	8709 (92.3)	2194 (96.4)	2385 (91.6)

^aRegimen included modified FOLFIRINOX.

^bPatients may have belonged to more than one category.

1L, first-line; BRCA, BReast CAncer gene; ECOG PS, Eastern Cooperative Oncology Group performance status; FOLFIRINOX, folinic acid (leucovorin), fluorouracil, irinotecan, oxaliplatin; Gem-Nab, gemcitabine plus nab-paclitaxel; mPAC, metastatic pancreatic adenocarcinoma; SD, standard deviation; y, years.

Supplementary Table 2. Treatment patterns by line of therapy and practice site

Treatment regimen, n (%)	1L (n = 6279)	2L (n = 2460)	3L (n = 814)
<i>Treated in community center</i>	<i>n = 4719</i>	<i>n = 1777</i>	<i>n = 564</i>
Gem-Nab	2031 (43.0)	722 (40.6)	87 (15.4)
FOLFIRINOX ^a	1653 (35.0)	139 (7.8)	28 (5.0)
Gem monotherapy	279 (5.9)	56 (3.2)	15 (2.7)
FOLFOX/FOLFIRI	250 (5.3)	147 (8.3)	90 (16.0)
Other FU-based regimens	148 (3.1)	92 (5.2)	28 (5.0)
NALIRIFOX and variants	142 (3.0)	358 (20.1)	152 (27.0)
Others ^b	82 (1.7)	94 (5.3)	62 (11.0)
FU monotherapy	73 (1.5)	64 (3.6)	33 (5.9)
Other Gem-based regimens	61 (1.3)	72 (4.1)	39 (6.9)
Clinical trials ^c	0 (0.0)	33 (1.9)	30 (5.3)
<i>Treated in academic center</i>	<i>n = 1560</i>	<i>n = 683</i>	<i>n = 250</i>
FOLFIRINOX ^a	624 (40.0)	43 (6.3)	13 (5.2)
Gem-Nab	574 (36.8)	292 (42.8)	39 (15.6)
Gem monotherapy	92 (5.9)	21 (3.1)	5 (2.0)
FOLFOX/FOLFIRI	80 (5.1)	53 (7.8)	47 (18.8)
Other FU-based regimens	59 (3.8)	32 (4.7)	12 (4.8)
NALIRIFOX and variants	43 (2.8)	92 (13.5)	54 (21.6)
Other Gem-based regimens	33 (2.1)	27 (4.0)	26 (10.4)
Others ^b	29 (1.9)	44 (6.4)	18 (7.2)
FU monotherapy	26 (1.7)	27 (4.0)	6 (2.4)
Clinical trials ^c	0 (0.0)	52 (7.6)	30 (12.0)

^aRegimen included modified FOLFIRINOX.

^bTreatment regimens used by < 20% of patients were collectively grouped as "Others."

^cAny treatment regimen that included an investigational agent.

1L, first-line; 2L, second-line; 3L, third-line; FOLFIRINOX, folinic acid (leucovorin), fluorouracil, irinotecan, oxaliplatin; FOLFOX, folinic acid, fluorouracil, oxaliplatin; FOLFIRI, folinic acid, fluorouracil, irinotecan; FU, fluorouracil; Gem, gemcitabine; Gem-Nab, gemcitabine plus nab-paclitaxel; NALIRIFOX, nanoparticle albumin-bound irinotecan, fluorouracil, leucovorin, oxaliplatin.

- Among patients treated in a community center, 29.2% (n = 1946/6665) did not receive 1L treatment within 180 days of metastatic diagnosis versus 43.8% (n = 1214/2774) of those treated in an academic center
- Mean (SD) time from metastatic diagnosis to receiving the first dose of 1L therapy was 26.5 (25.3) days for patients treated in community centers and 27.9 (28.2) days of those treated in academic centers